Supernus Pharmaceuticals Revenue vs. EBITDA
| SUPN Stock | USD 36.10 0.12 0.33% |
Total Revenue | First Reported 2008-12-31 | Previous Quarter 168.3 M | Current Value 175.7 M | Quarterly Volatility 62.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.82 | 0.8621 |
|
|
For Supernus Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Supernus Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Supernus Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Supernus Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Supernus Pharmaceuticals over time as well as its relative position and ranking within its peers.
Supernus |
Supernus Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out World Market Map.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Supernus Pharmaceuticals EBITDA vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Supernus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Supernus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Supernus Pharmaceuticals is rated below average in revenue category among its peers. It also is rated below average in ebitda category among its peers totaling about 0.15 of EBITDA per Revenue. The ratio of Revenue to EBITDA for Supernus Pharmaceuticals is roughly 6.75 . At this time, Supernus Pharmaceuticals' Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Supernus Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Supernus Revenue vs. Competition
Supernus Pharmaceuticals is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 284.92 Billion. Supernus Pharmaceuticals adds roughly 607.52 Million in revenue claiming only tiny portion of equities under Health Care industry.
Supernus EBITDA vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Supernus Pharmaceuticals |
| = | 607.52 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Supernus Pharmaceuticals |
| = | 90.04 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Supernus EBITDA Comparison
Supernus Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Supernus Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Supernus Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Supernus Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Supernus Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Supernus Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -593 K | -563.4 K | |
| Operating Income | -5.3 M | -5 M | |
| Income Before Tax | 2.8 M | 2.6 M | |
| Total Other Income Expense Net | 8 M | 8.4 M | |
| Net Income | 1.3 M | 1.3 M | |
| Income Tax Expense | 1.5 M | 1.4 M | |
| Net Income From Continuing Ops | 25.6 M | 49 M | |
| Non Operating Income Net Other | 16.8 M | 17.7 M | |
| Net Income Applicable To Common Shares | 69.8 M | 50.8 M | |
| Interest Income | 10.9 M | 12.5 M | |
| Net Interest Income | 6.9 M | 7.2 M | |
| Change To Netincome | -12.1 M | -11.5 M | |
| Net Income Per Share | 0.02 | 0.02 | |
| Income Quality | 84.41 | 88.63 | |
| Net Income Per E B T | 0.48 | 0.50 |
Supernus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Supernus Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Supernus Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Supernus Pharmaceuticals' important profitability drivers and their relationship over time.
Use Supernus Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Supernus Pharmaceuticals Pair Trading
Supernus Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.
The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Supernus Pharmaceuticals position
In addition to having Supernus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Copper Thematic Idea Now
Copper
Companies involved in production of copper. The Copper theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Copper Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
To fully project Supernus Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Supernus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Supernus Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.